相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ADI, autophagy and apoptosis Metabolic stress as a therapeutic option for prostate cancer
Randie H. Kim et al.
AUTOPHAGY (2009)
Arginine deprivation as a targeted therapy for cancer
L. Feun et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Diagnosis and treatment of hepatocellular carcinoma
Hashem B. El-Serag et al.
GASTROENTEROLOGY (2008)
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase
Tawnya L. Bowles et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Hepatocellular carcinoma: Trends of incidence and survival in Europe and the United States at the end of the 20th century
Riccardo Capocaccia et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis
Hashem B. El-Serag et al.
GASTROENTEROLOGY (2007)
Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase
Cheol-Yong Yoon et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion
Paul Ning-Man Cheng et al.
CANCER RESEARCH (2007)
FDA drug approval summary: Pegaspargase (Oncaspar (R)) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)
Patricia Anne Dinndorf et al.
ONCOLOGIST (2007)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
RECIST revisited: A review of validation studies on tumour assessment
P. Therasse et al.
EUROPEAN JOURNAL OF CANCER (2006)
Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies
PA Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The role of focal liver ablation in the treatment of unresectable primary and secondary malignant liver tumors
CJ Gannon et al.
SEMINARS IN RADIATION ONCOLOGY (2005)
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers - A method for identifying cancers sensitive to arginine deprivation
BJ Dillon et al.
CANCER (2004)
The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?
U Cillo et al.
JOURNAL OF HEPATOLOGY (2004)
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: Results from phase I/II studies
F Izzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth
IS Park et al.
BRITISH JOURNAL OF CANCER (2003)
Arginine deprivation, growth inhibition and tumour cell death: 2. Enzymatic degradation of arginine in normal and malignant cell cultures
R Philip et al.
BRITISH JOURNAL OF CANCER (2003)
Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties
FW Holtsberg et al.
JOURNAL OF CONTROLLED RELEASE (2002)
The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials
D Moher et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
分享论文
